Updated Nov. 9, 2011 at 6:48 a.m.
Targacept's drug pipeline
Image 1 of 3 · Next Image…
Research Triangle Park, N.C. — Targacept's compound called TC-5214, which targets major depressive disorder, "did not meet its primary endpoint" in the Phase 3 clinical trial, the Winston-Salem based biopharma company says. CEO says other trials will continue. Copyright 2013 WRAL Tech Wire. All rights reserved.
Drug failure sends Targacept stock down 60%
Post a comment
Print this blog postE-mail blog post
Share
Targacept's drug pipeline
Image 1 of 3 · Next Image…
Research Triangle Park, N.C. — Targacept's compound called TC-5214, which targets major depressive disorder, "did not meet its primary endpoint" in the Phase 3 clinical trial, the Winston-Salem based biopharma company says. CEO says other trials will continue. Copyright 2013 WRAL Tech Wire. All rights reserved.
Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows